Clinical Study of Xiongshao Capsule on Preventing Restenosis after Coronary Interventional Treatment

摘要

Objective: To evaluate the effect of Xiongshao capsule (XS) on preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: 108 coronary heart disease patients with successful coronary angioplasty or/and stenting were randomized into 55 cases in control (routine treatment) group and 53 cases in XS (routine treatment combined with XS) group. The recurrence of angina, changing of blood-stasis syndrome score (BSSS), restenosis index, exercise treadmill test, exercise-redistribution thallium scintigraphy and coronary angiography within 6 month after coronary angioplasty or/and stenting were observed. Logistic multivariate regression analysis was applied to analyze the related factor of restenosis demonstrated by angiography. Results: Follow-up angiography was performed in 42 patients including 18 cases in XS group (restenosis was observed in 7 patients) and 24 cases in control group (restenosis was observed in 17 patients), there was significant difference between the occurrence of restenosis in XS and that in control group(P<0.05). The occurrence of clinical end-point events (death, nonfatal target lesion myocardial infarction, coronary artery bypass graft surgery, or repeat target-vessel angioplasty) in XS group (18.8%) were significantly lower than that in control group (40%)(P<0.05). The recurrent angina was observed in 13 cases in XS group, there was significant difference as compared with 27 cases in control group(P<0.05). According to restenosis index, XS group (0.42 +-0.31) was significantly lower than control group (0.57 +-0.34) (P<0.01). There was also remarkable significance for the difference of base-line and follow-up BSSS between groups (P<0.01). Logistic multivariate stepwise regress analysis and multivariate regress analysis of the related factors with restenosis confirmed by coronary angiography showed that, the base-line BSSS and the difference of base-line and follow-up BSSS were important influencing factors on the occurrence of restenosis after interventional treatment (P<0.05). Conclusion: In this pilot study, XS could markedly reduce the occurrence of angiographic restenosis, clinical end-point events and recurrent angina, lower restenosis index and improve condition of blood-stasis after coronary angioplasty or/and stenting. The severity of blood-stasis syndrome was an important influencing factor on the occurrence of restenosis. The scoring of restenosis index can be applied to evaluating the therapeutic effect of drugs aiming at preventing restenosis after interventional treatment of coronary artery, it deserves to be further demonstrated.